

more definitely describe the subject matter of the claim. This is not a narrowing amendment, and Applicants have not surrendered any subject matter by this amendment. The Office's concerns over the terms "the resulting grouping", "which remain in each case", and "X" have also been addressed by this amendment. Again, this amendment is not narrowing and no subject matter has been surrendered by the amendment.


In view of the foregoing amendments and remarks, Applicants respectfully request the reconsideration and reexamination of this application and the timely allowance of the pending claims. Further, because the Office has found the elected claims allowable, it is required to rejoin non-elected process and method claims which include all limitations of the composition claims. See MPEP § 821.04. Applicants hereby request that the Office rejoin and examine these claims and find them allowable.

Please grant any extensions of time required to enter this response and charge any required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 3, 2002

By: 
Eric W. Adcock
Reg. No. 43,461





RECEIVED

APR 05 2007

TECH CENTER 1600/2222

The following Appendix provides a marked-up copy of each amendment made to the claims:

1. (Amended) A substituted norbornylamino [derivative] compound having exo-configured nitrogen and an endo-fused five-, six- or seven-membered ring of the formula I or a pharmaceutically acceptable salt or trifluoroacetate thereof, or having exo-configured nitrogen and an exo-fused five-, six- or seven-membered ring of the formula I a or a pharmaceutically acceptable salt or trifluoroacetate thereof



in which:

- A is (C₁-C₄)-alkylene;
S1 is a free electron pair or (C₁-C₄)-alkyl;
S2 is (C₁-C₄)-alkyl or H;

where, if S1 and S2 are alkyl, [X⁻ in the resulting grouping] a group $[\text{N}^+(\text{S1S2})-\text{X}^-]$ results, wherein X⁻ corresponds to a pharmacologically acceptable anion or trifluoroacetate;

- B is a saturated or unsaturated five-, six- or seven-membered carbon ring which may be mono- or, independently of one another, polysubstituted by oxo, hydroxyl, (C₁-C₄)-alkoxy and (C₁-C₄)-alkyl;

and

R1, R2, R3, R4 and R5

are, independently of one another, H, OH, F, Cl, Br, I, CN, NO₂, amidino, -CO₂R(11), -CONR(11)R(12), -SO_rR(11), -SO_sNR(11)-R(12), (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyloxy, hydroxy-(C₁-C₄)-alkyl, (C₃-C₇)-cycloalkoxy or phenyloxy,

where phenyl is unsubstituted or substituted by up to three substituents, which are independent of one another and are F, Cl, Br, or methoxy;

amino, (C₁-C₄)-alkylamino, di-(C₁-C₄)-alkylamino, amino-(C₁-C₄)-alkyl, di-(C₁-C₄)-alkylamino-(C₁-C₄)-alkyl, (C₁-C₄)-alkylamino-(C₁-C₄)-alkyl,

US 097340080AP1



Creation date: 15-07-2003
Indexing Officer: VKIM1 - VANNAROTH KIM
Team: OIPEBackFileIndexing
Dossier: 09734008

Legal Date: 03-01-2002

No.	Doccode	Number of pages
1	A...	3
2	XT/	2

Total number of pages: 5

Remarks:

Order of re-scan issued on